Asthma: Developments in targeted therapy

Expert Review of Clinical Immunology

Volumn 8, Issue 1, 2012, Pages 13-15

  Matucci, Andrea ^a   Vultaggio, Alessandra ^a   Ridolo, Erminia ^b   Maggi, Enrico ^a   Canonica, Giorgio Walter ^c   Rossi, Oliviero ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

asthma; biological agents; targeted therapy

Indexed keywords

ABATACEPT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CYTOKINE; DACLIZUMAB; EOTAXIN; ETANERCEPT; GOLIMUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 25; INTERLEUKIN 3; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LUMILIXIMAB; MEPOLIZUMAB; MONTELUKAST; OMALIZUMAB; PASCOLIZUMAB; PITRAKINRA; RG 7449; THYMIC STROMAL LYMPHOPOIETIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASTHMA; BRONCHOSPASM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; INFLAMMATION; NOTE; PHENOTYPE;

ANIMALS; ASTHMA; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 83455217697     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.71     Document Type: Note

References (14)

1. Bateman ED, Bousquet J, Busse WW et al. Stability of asthma control with regular treatment: an analysis of the gaining optimal asthma controL (GOAL) study. Allergy 63, 932-938 (2008).
2. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 368, 804-813 (2006).
3. Price D, Musgrave SD, Shepstone L et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N. Engl. J. Med. 364, 1695-1707 (2011).
4. Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184-190 (2001).
5. Brightling C, Berry M, Amrani Y. Targeting TNF-α: a novel therapeutic approach for asthma. J. Allergy Clin. Immunol. 121, 5-10 (2008).
6. Holgate ST, Noonan M, Chanez P et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a controlled trial. Eur. Respir. J. 37, 1352-1359 (2011).
7. Wenzel SE, Barnes PJ, Bleecker ER et al. A randomized, double-blind, placebo-controlled study of tumor necrosis-a blockade in severe persistent asthma. Am. J. Respir. Crit. Care Med. 179, 549-558 (2009).
8. Flood-Page P, Swenson C, Faiferman I et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 176, 1062-1071 (2007).
9. Wegmann M, Goggel R, Sel S et al. Effects of a low-molecular-weigh CCR-3 antagonist on chronic experimental asthma. Am. J. Respir. Cell Mol. Biol. 36, 61-67 (2007).
10. Hart TK, Blackburn MN, Brigham-Burke M et al. Preclinical efficacy and safety of pascolizumab (SB240683): a humanized anti-interleukin 4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol. 130, 93-100 (2002).
11. Holgate ST. Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches. J. Allergy Clin. Immunol. 128(3), 495-505 (2011).
12. Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A. A Phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm. Med. 10, 3-11 (2010).
13. Rosenwasser LJ, Busse WW, Lizambri RG, Olejnik TA, Totoritis MC. Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a Phase 1, single-dose, dose-escalating clinical trial. J. Allergy Clin. Immunol. 112, 563-570 (2003).
14. Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals from pathogenic mechanisms to prophylactic management. Curr. Opin. Allergy Clin. Immunol. 11, 262-268 (2011).